1887

Abstract

Colistin (polymyxin E) has emerged as a last-resort treatment option for multidrug-resistant infections.

Studies on the use, safety and efficacy of colistin in South Africa are limited.

. This study aims to describe the use of colistin and its clinical outcomes at a tertiary public hospital in South Africa.

We conducted a retrospective review of adult and paediatric patients who received parenteral colistin between 2015 and 2019.

A total of 69 patients (26 adults, 13 children and 30 neonates) were reviewed. was the most common causative pathogen isolated (70.1 %). Colistin was predominately used to treat septicaemia (75.4 %). It was primarily administered as definitive therapy (71.0 %) and as monotherapy (56.5 %). It was used in 11.5 % of adults with infections susceptible to other antibiotics. Loading doses of intravenous colistin were administered in only 15 (57.7 %) adult patients. Neurotoxicity and nephrotoxicity occurred in 5.8 % and 43.5 % of patients, respectively. Clinical cure was achieved in 37 (53.6 %) patients. On multivariate logistic regression analysis, adults [adjusted odds ratio (aOR), 25.54; 95 % CI, 2.73–238.65; < 0.01] and children (aOR, 8.56; 95 % CI, 1.06–69.10; < 0.05) had higher odds of death than neonates.

The study identified significant stewardship opportunities to improve colistin prescription and administration. Achieving optimal patient outcomes necessitates a multidisciplinary approach and vigilant monitoring of colistin use.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001840
2024-06-06
2024-06-14
Loading full text...

Full text loading...

References

  1. World Health Organization Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022 Geneva: World Health Organization; 2022
    [Google Scholar]
  2. Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist 2019; 12:3903–3910 [View Article] [PubMed]
    [Google Scholar]
  3. Lin TL, Chang PH, Chen IL, Lai WH, Chen YJ et al. Risk factors and mortality associated with multi-drug-resistant gram-negative bacterial infection in adult patients following abdominal surgery. J Hosp Infect 2022; 119:22–32 [View Article] [PubMed]
    [Google Scholar]
  4. Koyama Y, Kurosasa A, Tsuchiya A, Takakura K. A new antibiotic ‘Colistin’ produced by spore-forming soil bacteria. J Antibiot 1950; 3:457–458
    [Google Scholar]
  5. Matthew EF, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333–1341 [View Article] [PubMed]
    [Google Scholar]
  6. Tsuji BT, Pogue JM, Zavascki AP, Paul M, Daikos GL et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10–39 [View Article] [PubMed]
    [Google Scholar]
  7. El-Sayed Ahmed MAE, Zhong L-L, Shen C, Yang Y, Doi Y et al. Colistin and its role in the Era of antibiotic resistance: an extended review (2000-2019). Emerg Microbes Infect 2020; 9:868–885 [View Article] [PubMed]
    [Google Scholar]
  8. Labuschagne Q, Schellack N, Gous A, Bronkhorst E, Schellack G et al. Colistin: adult and paediatric guideline for South Africa, 2016. S Afr J Infect Dis 2016; 31:3–7 [View Article]
    [Google Scholar]
  9. Coetzee J, Corcoran C, Prentice E, Moodley M, Mendelson M et al. Emergence of plasmid-mediated colistin resistance (MCR-1) among Escherichia coli isolated from South African patients. S Afr Med J 2016; 106:35–36 [View Article] [PubMed]
    [Google Scholar]
  10. Sweileh WM. Global research publications on irrational use of antimicrobials: call for more research to contain antimicrobial resistance. Global Health 2021; 17:94 [View Article] [PubMed]
    [Google Scholar]
  11. Machowska A, Stålsby Lundborg C. Drivers of irrational use of antibiotics in Europe. Int J Environ Res Public Health 2018; 16:27 [View Article] [PubMed]
    [Google Scholar]
  12. Majavie L, Johnston D, Messina A. A retrospective review of colistin utilisation at a tertiary care academic hospital in South Africa. S Afr J Infect Dis 2021; 36:205 [View Article] [PubMed]
    [Google Scholar]
  13. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50:1953–1958 [View Article] [PubMed]
    [Google Scholar]
  14. Ofer-Shiber S, Molad Y. Association of the Charlson comorbidity index with renal outcome and all-cause mortality in antineutrophil cytoplasmatic antibody-associated vasculitis. Medicine 2014; 93:e152 [View Article] [PubMed]
    [Google Scholar]
  15. Al-Naimi MS, Rasheed HA, Hussien NR, Al-Kuraishy HM, Al-Gareeb AI. Nephrotoxicity: role and significance of renal biomarkers in the early detection of acute renal injury. J Adv Pharm Technol Res 2019; 10:95–99 [View Article] [PubMed]
    [Google Scholar]
  16. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011; 1:14 [View Article] [PubMed]
    [Google Scholar]
  17. Messina AP, Brink AJ, Richards GA, Van Vuuren S. Opportunities to optimise colistin stewardship in hospitalised patients in South Africa: results of a multisite utilisation audit. S Afr Med J 2018; 108:28–32 [View Article]
    [Google Scholar]
  18. Tamma PD, Newland JG, Pannaraj PS, Metjian TA, Banerjee R et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013; 32:17–22 [View Article] [PubMed]
    [Google Scholar]
  19. Landersdorfer CB, Nation RL. Colistin: how should it be dosed for the critically ill?. Semin Respir Crit Care Med 2015; 36:126–135 [View Article] [PubMed]
    [Google Scholar]
  20. Carrara E, Savoldi A, Piddock LJV, Franceschi F, Ellis S et al. Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations. Clin Microbiol Infect 2022; 28:66–72 [View Article] [PubMed]
    [Google Scholar]
  21. Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A et al. The association between empirical antibiotic treatment and mortality in severe infections caused by carbapenem-resistant gram-negative bacteria: a prospective study. Clin Infect Dis 2018; 67:1815–1823 [View Article] [PubMed]
    [Google Scholar]
  22. Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M et al. Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21:1106 [View Article] [PubMed]
    [Google Scholar]
  23. Karli A, Paksu MS, Karadag A, Belet N, Paksu S et al. Colistin use in pediatric intensive care unit for severe nosocomial infections: experience of an university hospital. Ann Clin Microbiol Antimicrob 2013; 12:32 [View Article] [PubMed]
    [Google Scholar]
  24. Chien HT, Lin YC, Sheu CC, Hsieh KP, Chang JS. Is colistin-associated acute kidney injury clinically important in adults? a systematic review and meta-analysis. Int J Antimicrob Agents 2020; 55:105889 [View Article] [PubMed]
    [Google Scholar]
  25. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392–2396 [View Article] [PubMed]
    [Google Scholar]
  26. Nigam A, Kumari A, Jain R, Batra S. Colistin neurotoxicity: revisited. BMJ Case Rep 2015; 2015:bcr2015210787 [View Article] [PubMed]
    [Google Scholar]
  27. Benattar YD, Omar M, Zusman O, Yahav D, Zak-Doron Y et al. The effectiveness and safety of high-dose colistin: prospective cohort study. Clin Infect Dis 2016; 63:1605–1612 [View Article] [PubMed]
    [Google Scholar]
  28. Sorlí L, Luque S, Segura C, Campillo N, Montero M et al. Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infect Dis 2017; 17:11 [View Article] [PubMed]
    [Google Scholar]
  29. Babar ZU, Dodani SK, Nasim A. Treatment outcome and adverse effects of colistin in adult patients with carbapenem-resistant gram-negative bacteremia from Pakistan. Int J Infect Dis 2021; 106:171–175 [View Article] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001840
Loading
/content/journal/jmm/10.1099/jmm.0.001840
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error